Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Peg-IFNα-2b in NA-suppressed Chronic Hepatitis B
NCT06457477Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of sintilimab in Chronic Hepatitis B (CHB), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Rate of HBsAg loss at 48 weeks. Started Jun 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06457477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06457477.